Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Harvard Business School

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,387,089

« Back to Dashboard

Summary for Patent: 4,387,089

Title: 4-(1,1-Dimethylethyl)-4'-methoxydibenzoylmethane
Abstract:The novel 4-(1,1-Dimethylethyl)-4'-methoxydibenzoylmethane is useful as a sunscreen agent. It exhibits outstanding UV-A absorbing qualities in that it brings about a considerable retardation in the ageing of the skin with excellent skin tolerance and stability (light, heat and moisture). 4-(1,1-Dimethylethyl)-4'-methoxydibenzoylmethane furthermore improves the protective action of UV B-filters, i.e. of substances which absorb the erythema-producing UV B-radiation in the range of about 290 to 320 mm.
Inventor(s): De Polo; Karl-Fred (Onex, CH)
Assignee: Givaudan Corporation (Clifton, NJ)
Application Number:06/264,774
Patent Claim Types:
see list of patent claims
Compound; Composition; Process; Use; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,387,089

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland11639/78Nov 13, 1978
Switzerland7686/79Aug 23, 1979

International Patent Family for Patent: 4,387,089

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Switzerland642536► Subscribe
Germany2945125► Subscribe
France2440933► Subscribe
United Kingdom2038807► Subscribe
JapanS5566535► Subscribe
JapanS6116258► Subscribe
Netherlands190101► Subscribe
Netherlands7907446► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
Argus Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus